The article "Glycolysis: an emerging regulator of osteoarthritis" by Dingming Jiang, Jianan Guo, Yingquan Liu, Wenxin Li, and Dezhaol Lu explores the role of glycolysis in the pathogenesis and treatment of osteoarthritis (OA). OA is a common joint disease affecting millions worldwide, with increasing prevalence due to factors such as metabolic syndrome and aging. The authors highlight the importance of metabolic disturbances in OA, particularly the dysregulation of glycolysis, which is a key energy source for chondrocytes. They discuss how glycolytic abnormalities contribute to cartilage degeneration, synovial inflammation, and subchondral bone changes. Key enzymes and metabolites involved in glycolysis, such as pyruvate kinase M2 (PKM2), hexokinase 2 (HK2), lactate dehydrogenase A (LDHA), and 6-phosphofructo-1-kinase 3 (PFKFB3), are reviewed for their roles in OA progression. The article also examines the relationship between glycolysis and programmed cell death (PCD), including apoptosis, and suggests that targeting glycolysis could be a potential therapeutic approach to alleviate OA symptoms. The authors conclude by discussing the future directions for studying glycolysis in OA, emphasizing the need for further research to develop effective treatments.The article "Glycolysis: an emerging regulator of osteoarthritis" by Dingming Jiang, Jianan Guo, Yingquan Liu, Wenxin Li, and Dezhaol Lu explores the role of glycolysis in the pathogenesis and treatment of osteoarthritis (OA). OA is a common joint disease affecting millions worldwide, with increasing prevalence due to factors such as metabolic syndrome and aging. The authors highlight the importance of metabolic disturbances in OA, particularly the dysregulation of glycolysis, which is a key energy source for chondrocytes. They discuss how glycolytic abnormalities contribute to cartilage degeneration, synovial inflammation, and subchondral bone changes. Key enzymes and metabolites involved in glycolysis, such as pyruvate kinase M2 (PKM2), hexokinase 2 (HK2), lactate dehydrogenase A (LDHA), and 6-phosphofructo-1-kinase 3 (PFKFB3), are reviewed for their roles in OA progression. The article also examines the relationship between glycolysis and programmed cell death (PCD), including apoptosis, and suggests that targeting glycolysis could be a potential therapeutic approach to alleviate OA symptoms. The authors conclude by discussing the future directions for studying glycolysis in OA, emphasizing the need for further research to develop effective treatments.